U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H12I3NO4
Molecular Weight 650.9741
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LIOTHYRONINE

SMILES

c1cc(c(cc1Oc2c(cc(cc2I)C[C@@]([H])(C(=O)O)N)I)I)O

InChI

InChIKey=AUYYCJSJGJYCDS-LBPRGKRZSA-N
InChI=1S/C15H12I3NO4/c16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22/h1-4,6,12,20H,5,19H2,(H,21,22)/t12-/m0/s1

HIDE SMILES / InChI

Molecular Formula C15H12I3NO4
Molecular Weight 650.9741
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/535845 | https://www.ncbi.nlm.nih.gov/pubmed/4453291 | https://www.ncbi.nlm.nih.gov/pubmed/16179385

Rathyronine is racemic mixture of Liothyronine (L-Triiodothyronine) and D-Triiodothyronine. Liothyronine (traid name CYTOMEL®) is a T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than its prohormone thyroxine. D-Triiodothyronine may be used to treatment hyperlipidemia, hypothyroidism, euthyroid goiters, ets. Unfortunately there are limited research related Rathyronine or D-Triiodothyronine activity.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CYTOMEL

Approved Use

Thyroid hormone drugs are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism. 2. As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s) and multinodular goiter. 3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy.

Launch Date

-4.3079041E11
Primary
CYTOMEL

Approved Use

Thyroid hormone drugs are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism. 2. As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s) and multinodular goiter. 3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy.

Launch Date

-4.3079041E11
Diagnostic
CYTOMEL

Approved Use

Thyroid hormone drugs are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism. 2. As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s) and multinodular goiter. 3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy.

Launch Date

-4.3079041E11
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
346 ng/dL
50 μg 1 times / day multiple, oral
dose: 50 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LIOTHYRONINE SODIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
342 ng/dL
50 μg 1 times / day multiple, oral
dose: 50 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LIOTHYRONINE SODIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
404 ng/dL
50 μg 1 times / day multiple, oral
dose: 50 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LIOTHYRONINE SODIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4370 ng × h/dL
50 μg 1 times / day multiple, oral
dose: 50 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LIOTHYRONINE SODIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4740 ng × h/dL
50 μg 1 times / day multiple, oral
dose: 50 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LIOTHYRONINE SODIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
4926 ng × h/dL
50 μg 1 times / day multiple, oral
dose: 50 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LIOTHYRONINE SODIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
12929 ng × h/dL
50 μg 1 times / day multiple, oral
dose: 50 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LIOTHYRONINE SODIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
13938 ng × h/dL
50 μg 1 times / day multiple, oral
dose: 50 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LIOTHYRONINE SODIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
22.04 h
50 μg 1 times / day multiple, oral
dose: 50 μg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LIOTHYRONINE SODIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
10794.4 ug 2 times / day multiple, oral
Overdose
Dose: 10794.4 ug, 2 times / day
Route: oral
Route: multiple
Dose: 10794.4 ug, 2 times / day
Sources: Page: p.2
unhealthy, 20
n = 1
Health Status: unhealthy
Condition: Fatigue
Age Group: 20
Sex: M
Population Size: 1
Sources: Page: p.2
Disc. AE: Anxiety, Palpitations...
AEs leading to
discontinuation/dose reduction:
Anxiety (severe)
Palpitations
Agitation
Shortness of breath
Irritability
Tachycardia
Tremor
Sources: Page: p.2
15000 ug 2 times / day multiple, oral
Overdose
Dose: 15000 ug, 2 times / day
Route: oral
Route: multiple
Dose: 15000 ug, 2 times / day
Sources: Page: p.2
unhealthy, 30
n = 1
Health Status: unhealthy
Condition: Hypothyroidism
Age Group: 30
Sex: F
Population Size: 1
Sources: Page: p.2
Disc. AE: Nausea, Vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea
Vomiting
Abdominal pain
Headache (severe)
Confusion
Disorientation
Diplopia
Sources: Page: p.2
50 ug 2 times / day multiple, oral
Highest studied dose
Dose: 50 ug, 2 times / day
Route: oral
Route: multiple
Dose: 50 ug, 2 times / day
Sources: Page: p.3
unhealthy, 39 ± 6.2
n = 2
Health Status: unhealthy
Condition: Multiple sclerosis
Age Group: 39 ± 6.2
Sex: M+F
Population Size: 2
Sources: Page: p.3
DLT: Anxiety, Tachycardia...
Dose limiting toxicities:
Anxiety (50%)
Tachycardia (50%)
Loose stools (100%)
Sources: Page: p.3
37.5 ug 2 times / day multiple, oral
MTD
Dose: 37.5 ug, 2 times / day
Route: oral
Route: multiple
Dose: 37.5 ug, 2 times / day
Sources: Page: p.3
unhealthy, 39 ± 6.2
n = 4
Health Status: unhealthy
Condition: Multiple sclerosis
Age Group: 39 ± 6.2
Sex: M+F
Population Size: 4
Sources: Page: p.3
AEs

AEs

AESignificanceDosePopulation
Agitation Disc. AE
10794.4 ug 2 times / day multiple, oral
Overdose
Dose: 10794.4 ug, 2 times / day
Route: oral
Route: multiple
Dose: 10794.4 ug, 2 times / day
Sources: Page: p.2
unhealthy, 20
n = 1
Health Status: unhealthy
Condition: Fatigue
Age Group: 20
Sex: M
Population Size: 1
Sources: Page: p.2
Irritability Disc. AE
10794.4 ug 2 times / day multiple, oral
Overdose
Dose: 10794.4 ug, 2 times / day
Route: oral
Route: multiple
Dose: 10794.4 ug, 2 times / day
Sources: Page: p.2
unhealthy, 20
n = 1
Health Status: unhealthy
Condition: Fatigue
Age Group: 20
Sex: M
Population Size: 1
Sources: Page: p.2
Palpitations Disc. AE
10794.4 ug 2 times / day multiple, oral
Overdose
Dose: 10794.4 ug, 2 times / day
Route: oral
Route: multiple
Dose: 10794.4 ug, 2 times / day
Sources: Page: p.2
unhealthy, 20
n = 1
Health Status: unhealthy
Condition: Fatigue
Age Group: 20
Sex: M
Population Size: 1
Sources: Page: p.2
Shortness of breath Disc. AE
10794.4 ug 2 times / day multiple, oral
Overdose
Dose: 10794.4 ug, 2 times / day
Route: oral
Route: multiple
Dose: 10794.4 ug, 2 times / day
Sources: Page: p.2
unhealthy, 20
n = 1
Health Status: unhealthy
Condition: Fatigue
Age Group: 20
Sex: M
Population Size: 1
Sources: Page: p.2
Tachycardia Disc. AE
10794.4 ug 2 times / day multiple, oral
Overdose
Dose: 10794.4 ug, 2 times / day
Route: oral
Route: multiple
Dose: 10794.4 ug, 2 times / day
Sources: Page: p.2
unhealthy, 20
n = 1
Health Status: unhealthy
Condition: Fatigue
Age Group: 20
Sex: M
Population Size: 1
Sources: Page: p.2
Tremor Disc. AE
10794.4 ug 2 times / day multiple, oral
Overdose
Dose: 10794.4 ug, 2 times / day
Route: oral
Route: multiple
Dose: 10794.4 ug, 2 times / day
Sources: Page: p.2
unhealthy, 20
n = 1
Health Status: unhealthy
Condition: Fatigue
Age Group: 20
Sex: M
Population Size: 1
Sources: Page: p.2
Anxiety severe
Disc. AE
10794.4 ug 2 times / day multiple, oral
Overdose
Dose: 10794.4 ug, 2 times / day
Route: oral
Route: multiple
Dose: 10794.4 ug, 2 times / day
Sources: Page: p.2
unhealthy, 20
n = 1
Health Status: unhealthy
Condition: Fatigue
Age Group: 20
Sex: M
Population Size: 1
Sources: Page: p.2
Abdominal pain Disc. AE
15000 ug 2 times / day multiple, oral
Overdose
Dose: 15000 ug, 2 times / day
Route: oral
Route: multiple
Dose: 15000 ug, 2 times / day
Sources: Page: p.2
unhealthy, 30
n = 1
Health Status: unhealthy
Condition: Hypothyroidism
Age Group: 30
Sex: F
Population Size: 1
Sources: Page: p.2
Confusion Disc. AE
15000 ug 2 times / day multiple, oral
Overdose
Dose: 15000 ug, 2 times / day
Route: oral
Route: multiple
Dose: 15000 ug, 2 times / day
Sources: Page: p.2
unhealthy, 30
n = 1
Health Status: unhealthy
Condition: Hypothyroidism
Age Group: 30
Sex: F
Population Size: 1
Sources: Page: p.2
Diplopia Disc. AE
15000 ug 2 times / day multiple, oral
Overdose
Dose: 15000 ug, 2 times / day
Route: oral
Route: multiple
Dose: 15000 ug, 2 times / day
Sources: Page: p.2
unhealthy, 30
n = 1
Health Status: unhealthy
Condition: Hypothyroidism
Age Group: 30
Sex: F
Population Size: 1
Sources: Page: p.2
Disorientation Disc. AE
15000 ug 2 times / day multiple, oral
Overdose
Dose: 15000 ug, 2 times / day
Route: oral
Route: multiple
Dose: 15000 ug, 2 times / day
Sources: Page: p.2
unhealthy, 30
n = 1
Health Status: unhealthy
Condition: Hypothyroidism
Age Group: 30
Sex: F
Population Size: 1
Sources: Page: p.2
Nausea Disc. AE
15000 ug 2 times / day multiple, oral
Overdose
Dose: 15000 ug, 2 times / day
Route: oral
Route: multiple
Dose: 15000 ug, 2 times / day
Sources: Page: p.2
unhealthy, 30
n = 1
Health Status: unhealthy
Condition: Hypothyroidism
Age Group: 30
Sex: F
Population Size: 1
Sources: Page: p.2
Vomiting Disc. AE
15000 ug 2 times / day multiple, oral
Overdose
Dose: 15000 ug, 2 times / day
Route: oral
Route: multiple
Dose: 15000 ug, 2 times / day
Sources: Page: p.2
unhealthy, 30
n = 1
Health Status: unhealthy
Condition: Hypothyroidism
Age Group: 30
Sex: F
Population Size: 1
Sources: Page: p.2
Headache severe
Disc. AE
15000 ug 2 times / day multiple, oral
Overdose
Dose: 15000 ug, 2 times / day
Route: oral
Route: multiple
Dose: 15000 ug, 2 times / day
Sources: Page: p.2
unhealthy, 30
n = 1
Health Status: unhealthy
Condition: Hypothyroidism
Age Group: 30
Sex: F
Population Size: 1
Sources: Page: p.2
Loose stools 100%
DLT
50 ug 2 times / day multiple, oral
Highest studied dose
Dose: 50 ug, 2 times / day
Route: oral
Route: multiple
Dose: 50 ug, 2 times / day
Sources: Page: p.3
unhealthy, 39 ± 6.2
n = 2
Health Status: unhealthy
Condition: Multiple sclerosis
Age Group: 39 ± 6.2
Sex: M+F
Population Size: 2
Sources: Page: p.3
Anxiety 50%
DLT
50 ug 2 times / day multiple, oral
Highest studied dose
Dose: 50 ug, 2 times / day
Route: oral
Route: multiple
Dose: 50 ug, 2 times / day
Sources: Page: p.3
unhealthy, 39 ± 6.2
n = 2
Health Status: unhealthy
Condition: Multiple sclerosis
Age Group: 39 ± 6.2
Sex: M+F
Population Size: 2
Sources: Page: p.3
Tachycardia 50%
DLT
50 ug 2 times / day multiple, oral
Highest studied dose
Dose: 50 ug, 2 times / day
Route: oral
Route: multiple
Dose: 50 ug, 2 times / day
Sources: Page: p.3
unhealthy, 39 ± 6.2
n = 2
Health Status: unhealthy
Condition: Multiple sclerosis
Age Group: 39 ± 6.2
Sex: M+F
Population Size: 2
Sources: Page: p.3
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Neurofilament expression in cultured rat adenohypophysial cells.
2001
Hypothalamus-hypophysis-thyroid axis, triiodothyronine and antithyroid antibodies in patients with primary and secondary Sjögren's syndrome.
2001
Effect of transient early hyperthyroidism on onset of puberty in Suffolk ram lambs.
2001 Apr
Thyroid hormone increases pacemaker activity in rat neonatal atrial myocytes.
2001 Apr
The pituitary-thyroid axis in healthy men living under subarctic climatological conditions.
2001 Apr
Effect of thyroxine administration on the IGF/IGF binding protein system in neonatal and adult thyroidectomized rats.
2001 Apr
Expression and regulation of osteopontin and connective tissue growth factor transcripts in rat anterior pituitary.
2001 Apr
Habituation of thermal sensations, skin temperatures, and norepinephrine in men exposed to cold air.
2001 Apr
Variable effects of goitrogens in inducing precocious metamorphosis in sea lampreys (Petromyzon marinus).
2001 Apr 15
Side-effects of iodized oil administration in patients with simple goiter.
2001 Feb
Changes in serum thyroid hormone levels in newborn calves as a diagnostic index of endemic goiter.
2001 Feb
[Diabetes mellitus caused by pancreatitis in a bull].
2001 Feb
Effects of melatonin in perimenopausal and menopausal women: a randomized and placebo controlled study.
2001 Feb
Thyroid function after bone marrow transplantation: possible association between immune-mediated thyrotoxicosis and hypothyroidism.
2001 Feb 15
Measurement of serum concentrations of free thyroxine, total thyroxine, and total triiodothyronine in cats with hyperthyroidism and cats with nonthyroidal disease.
2001 Feb 15
Ramadan fasting alters endocrine and neuroendocrine circadian patterns. Meal-time as a synchronizer in humans?
2001 Feb 23
Relationships between plasma levels of organochlorines, retinol and thyroid hormones from polar bears (Ursus maritimus) at Svalbard.
2001 Feb 23
What is the optimal treatment for hypothyroidism?
2001 Feb 5
Inhibition of T3 production in levothyroxine-treated female mice by the root extract of Convolvulus pluricaulis.
2001 Jan
Influence of selenium supplements on the post-traumatic alterations of the thyroid axis: a placebo-controlled trial.
2001 Jan
Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases.
2001 Jan
Direct effect of thyroxine on pig sphincter of Oddi contractility.
2001 Jan
[Diagnosis of hyperthyroidism].
2001 Jan
Impairment in cognitive and exercise performance during prolonged antarctic residence: effect of thyroxine supplementation in the polar triiodothyronine syndrome.
2001 Jan
Effect of acute elevation of IGF-I on circulating GH, TSH, insulin, IGF-II and IGFBP-3 levels in non-endocrine short stature (NESS).
2001 Jan
Effect of cold exposure on energy balance and liver respiratory capacity in post-weaning rats fed a high-fat diet.
2001 Jan
Endogenous depression, thyroid function and acupuncture.
2001 Jan
Influence of a high ambient temperature on lipid metabolism in the growing pig.
2001 Jan
Role of thyroid hormones in hepatic effects of peroxisome proliferators.
2001 Jan-Feb
An array of positioned nucleosomes potentiates thyroid hormone receptor action in vivo.
2001 Jun 8
The effects of triiodothyronine augmentation on antithrombin III levels in sepsis.
2001 Mar
Effects of caloric restriction on skeletal muscle mitochondrial proton leak in aging rats.
2001 Mar
Characterization of hepatic low-K(m) outer-ring deiodination in red drum (Sciaenops ocellatus).
2001 Mar
The biological relevance of thyroid hormone receptors in immortalized human umbilical vein endothelial cells.
2001 Mar
Perioperative considerations in a hypothyroid infant with hepatic haemangioma.
2001 Mar
Selenium decreases thyroglobulin concentrations but does not affect the increased thyroxine-to-triiodothyronine ratio in children with congenital hypothyroidism.
2001 Mar
Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism: a double blind, placebo-controlled study.
2001 Mar
Usefulness of thyrotropin (TSH)-releasing hormone test and nocturnal surge of TSH for diagnosis of isolated deficit of TSH secretion.
2001 Mar
Homogeneous enzyme immunoassay for triiodothyronine in serum.
2001 Mar
Distinct tissue-specific roles for thyroid hormone receptors beta and alpha1 in regulation of type 1 deiodinase expression.
2001 Mar
Hormone selectivity in thyroid hormone receptors.
2001 Mar
Thyroid hormones regulate pituitary growth hormone secretagogue receptor gene expression.
2001 Mar
Regulation of microglial development: a novel role for thyroid hormone.
2001 Mar 15
Insulin-like growth factor binding proteins in femoral and vertebral bone marrow stromal cells: expression and regulation by thyroid hormone and dexamethasone.
2001 Mar 26
Thyroid hormone promotes serine phosphorylation of p53 by mitogen-activated protein kinase.
2001 Mar 6
Regulation of mucous differentiation and mucin gene expression in the tracheobronchial epithelium.
2001 Mar 7
Effect of different drugs on the level of DNA-hydrolyzing polyclonal IgG antibodies in sera of patients with Hashimoto's thyroiditis and nontoxic nodal goiter.
2001 Mar-Apr
Thyroid hormone receptors in neonatal, prepubertal, and adult rat testis.
2001 Mar-Apr
Circannual pattern of hypothalamic-pituitary-thyroid (HPT) function and mood during extended antarctic residence.
2001 May
Transcriptional repression by thyroid hormone receptors. A role for receptor homodimers in the recruitment of SMRT corepressor.
2001 May 18
Patents

Sample Use Guides

Mild Hypothyroidism: Recommended starting dosage is 25 mcg daily. Daily dosage then may be increased by up to 25 mcg every 1 or 2 weeks. Usual maintenance dose is 25 to 75 mcg daily. Myxedema: Recommended starting dosage is 5 mcg daily. This may be increased by 5 to 10 mcg daily every 1 or 2 weeks. When 25 mcg daily is reached, dosage may be increased by 5 to 25 mcg every 1 or 2 weeks until a satisfactory therapeutic response is attained. Usual maintenance dose is 50 to 100 mcg daily. Congenital Hypothyroidism: Recommended starting dosage is 5 mcg daily, with a 5 mcg increment every 3 to 4 days until the desired response is achieved. Simple (non-toxic) Goiter: Recommended starting dosage is 5 mcg daily. This dosage may be increased by 5 to 10 mcg daily every 1 or 2 weeks. When 25 mcg daily is reached, dosage may be increased every week or two by 12.5 or 25 mcg. Usual maintenance dosage is 75 mcg daily.
Route of Administration: Oral
It was examined the involvement of phosphatidyl inositol 3 kinase (PI3K) pathway in mediating liothyronine (T3) effects by treating 3T3-L1 adipocytes with physiological (P=10 nM) or supraphysiological (SI=100 nM) T3 doses during one hour, in the absence or the presence of PI3K inhibitor (LY294002). The absence of any treatment was considered the control group (C). T3 increased thyroid hormone receptor alpha (TRa) mRNA expression in P (1.91+/-0.13, p<0.001), SI (2.14+/-0.44, p<0.001) compared to C group (1+/-0.08). This increase was completely abrogated by LY294002 in P (0.53+/-0.03, p<0.001) and SI (0.31+/-0.03, p<0.001). To examine whether TRa is directly induced by T3, the translation inhibitor cycloheximide (CHX) was used. The presence of CHX completely abrogated levels TRa mRNA in P (1.15+/-0.05, p>0.001) and SI (0.99+/-0.15, p>0.001), induced by T3.
Substance Class Chemical
Created
by admin
on Sat Jun 26 16:05:50 UTC 2021
Edited
by admin
on Sat Jun 26 16:05:50 UTC 2021
Record UNII
06LU7C9H1V
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LIOTHYRONINE
HSDB   INN   MI   USP-RS   VANDF   WHO-DD  
INN  
Official Name English
LIOTHYRONINE [MI]
Common Name English
CYRONINE
Brand Name English
T3
Common Name English
NSC-80203
Code English
LIOTHYRONINE [WHO-DD]
Common Name English
3,5,3'-TRIIODOTHYRONINE, L-
Common Name English
LEVOTHYROXINE SODIUM RELATED COMPOUND LIOTHYRONINE [USP]
Common Name English
LIOTHYRONINE [VANDF]
Common Name English
LIOTHYRONINE [USP]
Common Name English
O-(4-HYDROXY-3-IODOPHENYL)-3,5-DIIODO-L-TYROSINE
Systematic Name English
3,3',5-TRIIODO-L-THYRONINE
Systematic Name English
L-TYROSINE, O-(4-HYDROXY-3-IODOPHENYL)-3,5-DIIODO-
Systematic Name English
3,5,3'-TRIIODOTHYRONINE
Systematic Name English
RATHYRONINE, (S)-
Common Name English
ALANINE, 3-(4-(4-HYDROXY-3-IODOPHENOXY)-3,5-DIIODOPHENYL)-, L-
Systematic Name English
LEVOTHYROXINE SODIUM IMPURITY A [EP]
Common Name English
T-3
Common Name English
TRIIODOTHYRONINE
Systematic Name English
THYRONINE, 3,3',5-TRIIODO-, L-
Systematic Name English
(2S)-2-AMINO-3-(4-(4-HYDROXY-3-IODOPHENOXY)-3,5-DIIODOPHENYL)PROPANOIC ACID
Systematic Name English
LIOTHYRONINE [INN]
Common Name English
LIOTHYRONINE [HSDB]
Common Name English
LIOTHYRONINE [USP-RS]
Common Name English
Classification Tree Code System Code
CFR 21 CFR 862.1715
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
LOINC 83124-8
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
LOINC 26879-7
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
LOINC 83125-5
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
FDA ORPHAN DRUG 539116
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
NCI_THESAURUS C1553
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
WHO-VATC QH03AA03
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
NDF-RT N0000006165
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
CFR 21 CFR 862.1710
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
CFR 21 CFR 520.1284
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
LOINC 3053-6
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
LOINC 14930-2
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
WHO-ATC H03AA03
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
LOINC 3055-1
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
NDF-RT N0000175946
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
NCI_THESAURUS C886
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
LIVERTOX 1000
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
LOINC 70152-4
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
NDF-RT N0000006165
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
LOINC 35231-0
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
LOINC 57899-7
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
Code System Code Type Description
CAS
57164-27-9
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
SUPERSEDED
DRUG CENTRAL
1585
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
PRIMARY
EVMPD
SUB08527MIG
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
PRIMARY
EPA CompTox
6893-02-3
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
PRIMARY
USP_CATALOG
1368008
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
PRIMARY USP-RS
ECHA (EC/EINECS)
229-999-3
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
PRIMARY
RXCUI
10814
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
PRIMARY RxNorm
DRUG BANK
DB00279
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
PRIMARY
MERCK INDEX
M6835
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
PRIMARY Merck Index
HSDB
3110
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
PRIMARY
NCI_THESAURUS
C907
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
PRIMARY
INN
653
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
PRIMARY
FDA UNII
06LU7C9H1V
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
PRIMARY
LACTMED
Liothyronine
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
PRIMARY
CAS
6893-02-3
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
PRIMARY
WIKIPEDIA
LIOTHYRONINE
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
PRIMARY
ChEMBL
CHEMBL1544
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
PRIMARY
IUPHAR
2634
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
PRIMARY
MESH
D014284
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
PRIMARY
CAS
7013-53-8
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
SUPERSEDED
PUBCHEM
5920
Created by admin on Sat Jun 26 16:05:51 UTC 2021 , Edited by admin on Sat Jun 26 16:05:51 UTC 2021
PRIMARY
Related Record Type Details
RACEMATE -> ENANTIOMER
SALT/SOLVATE -> PARENT
LABELED -> NON-LABELED
TRANSPORTER -> SUBSTRATE
LABELED -> NON-LABELED
TRANSPORTER -> SUBSTRATE
SALT/SOLVATE -> PARENT
Related Record Type Details
PARENT -> METABOLITE ACTIVE
MAJOR
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
PARENT -> IMPURITY
The relative response factor is 1.00
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY